MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41391-025-01062-8

Медицинская библиотека · Prostate cancer and prostatic diseases · 2025

Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer.

Singhal Udit, Jiang Ralph, Proudfoot James A, Chase Elizabeth, Suresh Krithika, Davicioni Elai, Borza Tudor, Zelefsky Michael J, Davis Brian J, Stish Brad J, Karnes R Jeffrey, Freedland Stephen J, Terris Martha K, Aronson William J, Cooperberg Matthew R, Moraes Fabio Y, Berlin Alejandro, Deville Curtiland, Zaorsky Nicholas G, Roy Soumyajit, Jia Angela Y, Shoag Jonathan E, Jackson William C, Spratt Daniel E, Schipper Matthew, Morgan Todd M, Dess Robert T

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: Genomic classifiers are endorsed by guidelines and commonly used to inform prognosis in prostate cancer. We aimed to understand the distribution of genomic risk within the validated staging collaboration for cancer of the prostate (STAR-CAP) and propose a system integrating genomic and clinicopathologic risk. We hypothesized that genomic heterogeneity would have implications on risk estimates and may inform treatment decisions.

MATERIALS AND

METHODS

Genomic risk was assessed using the Decipher genomic classifier in two separate multi-institutional, prospectively collected population-based registries: (1) Decipher Genomics Resource for Intelligent Discovery (GRID) [n = 50,891] and (2) Michigan Urological Surgery Improvement Collaborative (MUSIC-Decipher) [n = 1602]. The primary endpoint was estimated prostate cancer-specific mortality (PCSM), and secondary endpoint was distant metastasis (DM). Marginal risk estimates provided by STAR-CAP were combined with hazard ratios of Decipher to calculate integrated risk estimates.

RESULTS

Median age and PSA was 68 years and 6.2 ng/mL in GRID, and 66 years and 10.5 ng/mL in MUSIC. The GRID population had 50.2%, 18.5%, and 31.4% with low-, intermediate-, and high-Decipher risk, compared to 48.0%, 16.2%, and 35.8% in MUSIC. Decipher-based genomic risk varied across STAR-CAP stages in both registries. Estimates of 10-year PCSM (0.1% to 48.8%) and DM (0.3%-72.9%) varied widely after integration of clinical-genomic risk. Use of an integrated Decipher-STAR-CAP system led to significant stage reclassification, including 23.4% upstaging and 45.6% downstaging at least one stage.

CONCLUSIONS

These findings suggest integration of genomic and clinicopathologic risk may lead to more nuanced risk assessment in prostate cancer and may help individualize treatment consideration.

Для цитирования: Singhal Udit, Jiang Ralph, Proudfoot James A, Chase Elizabeth, Suresh Krithika, Davicioni Elai, Borza Tudor, Zelefsky Michael J, Davis Brian J, Stish Brad J, Karnes R Jeffrey, Freedland Stephen J, Terris Martha K, Aronson William J, Cooperberg Matthew R, Moraes Fabio Y, Berlin Alejandro, Deville Curtiland, Zaorsky Nicholas G, Roy Soumyajit, Jia Angela Y, Shoag Jonathan E, Jackson William C, Spratt Daniel E, Schipper Matthew, Morgan Todd M, Dess Robert T. Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer.. Prostate cancer and prostatic diseases. 2025. DOI: 10.1038/s41391-025-01062-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.